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Infectious disease management of Staphylococcus aureus bac-
teremia (SAB) was surveyed through the Emerging Infections 
Network. Although there were areas of consensus, we found 
substantial practice variation in diagnostic evaluation and man-
agement of adult patients with SAB. These findings highlight 
opportunities for further research and guidance to define best 
practices.
Keywords. Staphylococcus aureus; bacteremia; infectious 
disease physicians.
Staphylococcus aureus bacteremia (SAB) is associated with high 
morbidity, mortality, and healthcare costs [1]. Infectious disease 
(ID) consultation for SAB has been associated with significant 
improvement in patient outcomes and increased adherence to 
best practices in SAB management such as follow-up blood 
cultures, echocardiography, source identification/control, and 
appropriate antibiotic therapy [2, 3]. However, little is known 
about practice patterns among ID physicians in scenarios where 
data are limited or inconclusive. We distributed a survey to 
members of the Emerging Infections Network (EIN) to assess 
physician practices in the management of SAB.
METHODS
The Infectious Diseases Society of America’s (IDSA) EIN is 
a network of practicing ID physicians in the United States 
and Canada, funded by the Centers for Disease Control and 
Prevention [4]. We developed an 11-question multiple-choice 
survey (Supplementary Materials) to assess adult ID specialist 
opinions and practice patterns in the management of SAB. 
The EIN distributed the survey via emailed weblink or fac-
simile on 5 January 2017. Two reminders at 1-week intervals 
were provided. Survey responses were analyzed using SAS 




Of 1286 active EIN physician members with an adult ID prac-
tice, 723 (56%) responded to this survey. Respondents (220/723 
[30%]) were more likely than nonrespondents (117/563 [21%]) 
to have ≥25 years of ID experience (P < .0001). No other signif-
icant differences were identified. Baseline practice characteris-
tics including clinical experience, practice type, and geographic 
location are provided in Supplementary Table 1. Fifty-four (7%) 
respondents did not manage SAB and opted out.
Diagnostic Evaluation of SAB
Repeat blood cultures and echocardiography are performed 
by the majority of respondents (Figure 1A). Most (599/667 
[90%]) indicated they would always perform a transthoracic 
echocardiogram (TTE). Those with <15  years of experi-
ence were more likely to always do a TTE (93% vs 86%; 
P  =  .01). A  transesophageal echocardiogram (TEE) would be 
performed on every patient with a negative TTE by 126 (19%) 
of respondents whereas 473 (71%) would only perform TEE 
under selected circumstances (Figure 1B). Those practicing in 
the Midwest, Northeast, or South [5] regions were more likely 
to always perform a TEE compared to those in the West or 
Canada/Puerto Rico (24% vs 11%; P = .009).
Nafcillin or Cefazolin for Methicillin-susceptible Staphylococcus aureus 
Endocarditis
For treatment of left-sided methicillin-susceptible S.  aureus 
(MSSA) endocarditis without CNS involvement, 32% chose 
cefazolin and 29% favored nafcillin, whereas 32% considered 
the 2 equivalent. Among the 215 who chose cefazolin, 207 pro-
vided a rationale, with most citing a combination of equal ef-
ficacy, less toxicity, dosing convenience, and cost. Among the 
193 who selected nafcillin, 169 provided a rationale, with most 
citing nafcillin as the “gold standard,” whereas others favored 
it due to inoculum effect or better CNS penetration for clini-
cally silent disease. Those with <5 (vs ≥5) years of experience 
were more likely to use cefazolin (39% vs 33%) whereas those 
with ≥15 (vs <15) years of experience were more likely to use 
nafcillin (37% vs 26%) (P = .048).
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Management of Methicillin-resistant S.  aureus Bacteremia and 
Endocarditis
When managing a patient with methicillin-resistant S.  au-
reus (MRSA) bacteremia and a vancomycin minimum in-
hibitory concentration (MIC) of 2  mg/L, a majority (336/665 
[51%]) of respondents would treat with vancomycin if clin-
ically responding, whereas 248 (37%) favored daptomycin 
and 29 (4%) chose ceftaroline. Less than 1% of respondents 
selected linezolid, telavancin, trimethoprim-sulfamethoxazole, 
or daptomycin plus ceftaroline. Respondents in a university or 
teaching hospital were more likely to use vancomycin compared 
with those in a community or Veterans Affairs/Defense 
Department hospital (55% vs 43%; P = .03).
In a patient with MRSA endocarditis and persistent bacte-
remia on day 6 of vancomycin, most (504/668 [75%]) would 
modify therapy. Alternative monotherapy was selected by 
245 (37%) respondents whereas 215 (32%) favored combina-
tion therapy (Figure 1C). Among those who chose another 
single agent, 193 (78%) selected daptomycin while 36 (15%) 
chose ceftaroline. The specific combination of daptomycin and 
ceftaroline was chosen by 66 (10%). Those practicing in the 
Midwest were most likely to choose alternative monotherapy 
(62%). Those in the Northeast and West were most likely to use 
combination therapy with daptomycin (28%; P = .04), and were 
more likely to use daptomycin and ceftaroline (15%) compared 
to those in the Midwest (5%) and South (7%) (P = .004).
The daptomycin dose used for MRSA bacteremia varied, with 
38%, 43%, and 17% of respondents selecting 6 mg/kg, 8 mg/kg, 
and 10–12  mg/kg, respectively. Doses of 10–12  mg/kg were 
most likely to be used in the Northeast and West (21% and 20%, 
respectively), while 6–8 mg/kg was most likely to be used in the 
Midwest (91%) (P = .0002).
Duration of Therapy
Most respondents managed SAB with at least 14 days of intra-
venous (IV) antibiotics in several scenarios. In a patient with 
MRSA bacteremia and a skin and soft tissue source, rapid clear-
ance of blood cultures, negative TTE, and no evidence of met-
astatic infection, most (491/669 [73%]) would treat with IV 
vancomycin for 14 days whereas 87 (13%) transitioned to oral 
antibiotics to complete a 14-day course. A  minority (24/669 
[4%]) would treat for 5–7 days with either oral or IV antibiotics 
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Figure 1. Practice patterns among survey respondents on the diagnostic evalu-
ation and management of Staphylococcus aureus bacteremia (SAB). A, Diagnostic 
workup routinely performed in the evaluation of a patient with SAB. B, Respondents 
indicating they would perform transthoracic echocardiogram (TTE) on every patient 
but only perform transesophageal echocardiogram (TEE) under these selected 
circumstances (n  =  473). C, Management of patient with methicillin-resistant 
Staphylococcus aureus endocarditis and persistent SAB on day 6 of vancomycin, 
with therapeutic trough and vancomycin MIC of .5  mg/L. D, Factors influencing 
decision to extend duration of therapy from 2 weeks to 4–6 weeks assuming 
negative echocardiography (TTE and/or TEE). Abbreviations: Abd, abdominal; cx, 
culture; CT, computed tomography; MRI, magnetic resonance imaging; MRSA, 
methicillin-resistant Staphylococcus aureus; TEE, transesophageal echocardiogram; 
TTE, transthoracic echocardiogram. *Among 222 respondents who commented on 
other clinical factors that would prompt TEE, common responses included presence 
of cardiac device or prosthetic valve (58 [26%]); clinical suspicion for infective en-
docarditis including embolic phenomenon or metastatic infection (43 [19%]); or TEE 
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In a patient with 1 of 2 blood cultures positive for MSSA, 
no obvious signs or symptoms of infection, a normal white 
blood cell count, negative repeat blood cultures, negative TTE, 
and no evidence of metastatic infection, most (445/664 [67%]) 
respondents would treat with IV antibiotics for 14 days whereas 
51 (8%) would treat for 4–6 weeks. A  minority (10%) would 
consider the cultures a contaminant and stop antibiotics.
Most respondents would extend treatment duration to 4–6 
weeks in the setting of SAB and a negative echocardiogram 
for patients with a prosthetic device or positive repeat blood 
cultures (Figure 1D).
Management of Septic Thrombophlebitis
Most respondents (467/657 [71%]) recommended 
anticoagulation in the setting of SAB and peripherally inserted 
central catheter–associated deep vein thrombosis after catheter 
removal. Duration of antimicrobial therapy varied with 52% of 
respondents treating for 4 weeks while 19% chose 2 weeks and 
25% chose 6 weeks.
DISCUSSION
SAB is a serious disease commonly managed by ID physicians. 
Most respondents performed repeat blood cultures and echo-
cardiography, and treated with IV therapy for at least 14 days. 
There were some areas of consensus, but this survey highlights 
considerable practice variation among respondents representing 
a wide breadth of ID practitioners in North America, including 
differences by years of experience, geographic region, and prac-
tice environment.
The IDSA MRSA treatment guidelines recommend echo-
cardiography in all patients with SAB, with TEE being the pre-
ferred modality due to its greater sensitivity [6]. Although the 
vast majority of respondents supported TTE as part of the di-
agnostic evaluation of SAB, only 19% of respondents indicated 
they would always perform a TEE. These findings are consistent 
with other studies that suggest routine use of TEE is infrequent 
[7]. TEE is an invasive procedure that has complication risks, is 
resource intensive, and may not be available at all centers. Some 
studies suggest that TEE may not be necessary for all cases of 
SAB and that clinical prediction rules may help with risk strat-
ification, but these require external validation [8]. The lack of 
concordance between guideline recommendations and current 
practice indicates a need for further research and guidance on 
the role of TEE among patients with SAB.
There was lack of consensus regarding the treatment of 
MSSA endocarditis, with respondents almost evenly dis-
tributed among cefazolin, nafcillin, or use of either drug, 
suggesting the need for evidence-based guidelines to define 
optimal therapy. Those with fewer years of experience fa-
vored cefazolin whereas more experienced clinicians pre-
ferred nafcillin. These differences may reflect a growing body 
of literature suggesting similar clinical outcomes and fewer 
drug-related adverse events with the use of cefazolin for MSSA 
bacteremia [9]. However, early reports of cefazolin treatment 
failure in the setting of endocarditis have led others to caution 
its use in high-inocula infections [10].
Although the presence of prosthetic devices or positive re-
peat blood cultures would prompt most to extend therapy to 
4–6 weeks, a smaller proportion of respondents were influenced 
by immunosuppression, diabetes, or community-onset bacte-
remia. Further guidance is needed to identify patients who are 
at increased risk of relapse or serious complications, in whom 
prolonged treatment duration may be warranted.
Consistent with guideline recommendations [6], clinical 
response influenced 51% of respondents to continue vanco-
mycin in a patient with MRSA bacteremia and vancomycin 
MIC of 2 μg/mL, although a substantial portion would switch 
to daptomycin. Observational studies examining the role of 
daptomycin vs vancomycin in management of MRSA bacte-
remia with high vancomycin MICs have yielded mixed results 
[11, 12], and a randomized controlled trial designed to eval-
uate this issue was recently terminated due to slow accrual [11]. 
Although 8  mg/kg was the most commonly selected dose of 
daptomycin, a sizable minority chose the US Food and Drug 
Administration label dose of 6 mg/kg for management of MRSA 
bacteremia. The substantial differences in management of the 
above scenario and treatment of persistent bacteremia highlight 
the lack of high-quality evidence in these areas.
Our study has several limitations. As with all voluntary 
surveys, selection bias could yield results not generalizable to 
all ID specialists. Response bias is possible and survey answers 
may not accurately reflect clinical practice. Although the value 
of ID consultation in SAB management has been established by 
multiple studies, this survey demonstrates that there remains 
ample opportunity to further define best practices and optimize 
management of this complex disease.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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